Milestone Pharmaceuticals Inc.
MISTNASDAQHealthcare● Active
$1.23
+$0.00(+0.00%)
Market Cap$105643332
P/E Ratio—
52W High$3.06
52W Low$1
Milestone Pharmaceuticals Inc. (MIST) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MIST · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.55M | $0.00M | $1.00M | $5.00M | $15.00M |
| Cost of Revenue | $0.11M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $1.43M | $0.00M | $1.00M | $5.00M | $15.00M |
| Gross Margin %(computed) | 92.63% | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $18.11M | $14.36M | $31.05M | $39.83M | $38.67M |
| G&A Expenses | $17.27M | $16.74M | $15.93M | $15.72M | $12.40M |
| Total Operating Expenses | $63.92M | $42.10M | $62.10M | $64.64M | $58.07M |
| Operating Income | ($62.48M) | ($42.10M) | ($61.10M) | ($59.64M) | ($43.07M) |
| Operating Margin %(computed) | — | — | — | — | -287.15% |
| Interest Income | $2.92M | $4.16M | $3.97M | $1.25M | $0.22M |
| Interest Expense | $3.84M | ($3.58M) | $2.55M | $0.00M | $0.00M |
| Income Before Tax | ($63.40M) | ($41.52M) | ($59.69M) | ($58.39M) | ($42.85M) |
| Income Tax Expense | ($0.34M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($63.06M) | ($41.52M) | ($59.69M) | ($58.39M) | ($42.85M) |
| Net Margin %(computed) | — | — | — | — | -285.69% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.75 | $-0.67 | $-1.39 | $-1.35 | $-1.02 |
| Wtd Avg Shares | 83.88M | 62.21M | 42.96M | 42.45M | 41.83M |
| EBITDA | ($62.14M) | ($37.83M) | ($57.04M) | ($58.30M) | ($42.98M) |
| EBITDA Margin %(computed) | — | — | — | — | -286.53% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Milestone Pharmaceuticals Inc. data
About Milestone Pharmaceuticals Inc. (MIST) Income Statement
Milestone Pharmaceuticals Inc. (MIST) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MIST reported revenue of $0.00B, gross profit of $0.00B (gross margin 92.63%), and net income of ($0.06B) — a net profit margin of -4078.78%.
Frequently asked questions
MIST · 4 questionsMilestone Pharmaceuticals Inc. (MIST) reported revenue of $0.00B for 2025, up —% year-over-year.
MIST revenueMIST salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08